10 July 2026
In plain English
Yesterday was the last day to submit written comments that would be placed directly in front of the 14 FDA panelists voting on July 23 whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be prescribed through specialty pharmacies. Late submissions still go to the FDA's record, but the panelists' briefing material is now sealed. Nothing today moved any forecast probability. Separately, Eli Lilly won a partial court ruling forcing the FDA to reconsider whether its next pipeline weight-loss drug retatrutide — which produced 28–30% weight loss in trials — qualifies as a "biologic" rather than a standard drug. The distinction matters: if it's a biologic, specialty pharmacies would never be able to make cheaper copies. The Medicare $50-a-month weight-loss drug program passed day 10 without incident.
Signal detail
Written comments deadline passed July 9 — panelists' briefing material sealed. No FACA challenge at T-13 days; challenge probability decaying toward ~5%. FDA staff recommendation against all 7 peptides remains the strongest informational anchor. BPC-157 remains the weakest safety case (35/36 published studies animal-only per ECRI/ISMP). Historian: in prior FDA advisory committee cycles, the committee-provided-comments deadline marks an informational inflection — after this point, only the staff recommendation and panelists' own expertise shape preparation. Next independent variable: public comment close July 22. 13 days to resolution.
Same comment-deadline lock-in. The 14-member panel continues to favor moderate 2-of-4 outcomes. BPC-157 (ulcerative colitis) and KPV (anti-inflammatory) remain strongest Cat 1 candidates. Bayesian: no new evidence; posterior unchanged. 13 days to resolution.
No launch announcement. Month 19 post-California-facility-acquisition — middle of 18–24-month M&A-to-launch base rate. OneTwenty 11+ weeks live, zero FDA enforcement. Next catalysts: PCAC July 23, Q2 earnings August. 174 days to resolution.
No new US adverse events. PCAC-503B concentration week July 23–30 in 13 days creates the dual-hook editorial window — journalists covering the hearing will encounter the 40% contamination rate and 775+ AE count in FDA briefing materials. 264 days to resolution.
Day 10 post-launch. No enrollment data — CMS reports quarterly. Absence of operational-failure headlines mildly positive. First pharmacy claims volume data expected mid-July. KFF clinical-eligible pool: 3.8M; 1M = 26% penetration in 6 months. 174 days to resolution.
First-party Katalys recovery accelerating: $2,349 / 7 conversions, strongest week since Eden Health pause (prior best $900/3). Three partners converting — Trim Rx ($1,200/4), Embody ($800/2), Gala Health ($349/1). GSC impressions 4,203 (+30%), clicks 83 (+54%), avg position 17.5 (from 21.3). CagriSema confirmed NOT approved; PDUFA ~October 2026. Retatrutide NDA Q4 2026. No peptide DTC affiliate programs. GLP-1 CPA dominance structural. 174 days to resolution.
Resolutions & upcoming
No forecasts resolved. Two forecasts resolve July 23 (13 days): - `bpc157-pcac-2026` (0.35 NOT Cat 1) - `pcac-july-multi-peptide` (0.70 ≥2 of 4 Cat 1)
How Barque got smarter today
- Comment-deadline-as-information-lock is a processable signal. The July 9 deadline sealed the informational environment the panel enters. Post-lock, only FDA staff follow-up briefings and panelists' own research shape preparation. The asymmetry: well-organized lobby submissions filed by July 9 (IACP, A4M, PCCA) are in the package; disorganized academic counter-submissions filed July 10–22 are not. Future FDA advisory committee forecasts should track this deadline explicitly.
- First-party revenue recovery validates multi-partner strategy. Katalys $2,349/7 conversions across 3 partners reduces the single-partner concentration risk that created the Eden Health revenue cliff. This is portfolio-thesis validation, not a forecast probability mover.
- Lilly retatrutide biologic lawsuit is a structural precedent. First proactive pharma lawsuit to prevent compounding access before approval. If Lilly wins, the shortage → compounding → brand-vs-compounded playbook is broken for future GLP-1s. Establishes a reference class for future compounding-access predictions.
- FACA challenge risk nearing floor. At T-13 no challenge filed. Adjusting from ~10% to ~5%. Sources sampled: FDA.gov (PCAC calendar, docket), CMS.gov (Medicare Bridge), Novo Nordisk IR, CNBC, NBC News, NPR, Bloomberg Law, Endpoints News, PeptideHub, HealingMaps, Kinetic Compounds, DVM360, retaweightloss.com. Tier 2: Reddit blocked (403).